By Michael Fleming The extraordinarily successful initial public offering by Prelude Therapeutics (PRLD) last month made clear investors’ immense confidence in prospects for the Wilmington biopharmaceutical company. Prelude’s market capitalization quickly shot past $1 billion, ...
WILMINGTON – After weeks of waiting and behind-the-scenes negotiating, Prelude Therapeutics closed its initial public offering Thursday night at its highest targeted price point of $19 a share, resulting in $158.2 million in proceeds. Prelude, ...
WILMINGTON – Prelude Therapeutics, a private biotechnology startup company headquartered at the Delaware Innovation Space, has set its sights on a $150 million initial public offering (IPO), increasing the sale by about 50% from its ...
WILMINGTON – Fresh off Series C funding closed last month, Prelude Therapeutics, a private life sciences start-up company headquartered in Alapocas, has announced that it is pursuing an initial public offering (IPO) worth as much ...
WILMINGTON – Prelude Therapeutics, a private life sciences start-up company, announced Aug. 24 that it has closed a $50 million Series C financing round, continuing its explosive growth in only four years. The new funds ...
Over the past five years, the bioscience industry in Delaware has undergone significant changes that were both negative and positive. Earlier this decade we lost about 12% of our jobs due to business decisions by ...
Movers, shakers, difference-makers Delaware has plenty of talented people, but who is set to make the biggest impact in 2019? Delaware Business Times asked industry leaders who they thought would be the biggest names in ...
By Dan Linehan Special to Delaware Business Times It’s natural to draw parallels between Kris Vaddi’s time discovering drugs at Incyte, where he spent 14 years, and his latest startup venture, Prelude Therapeutics. But there ...
A founding scientist and previous vice president of the pharmaceutical company Incyte is growing his next venture in Delaware. The state Council on Development Finance (CDF) voted Monday to recommend a performance-based grant package for Prelude Therapeutics. ...
The art of being a great client - Recently, I was reacquainted with The Art of Client Service, a must-read for any aspiring account executive eager to set his or her agency (and the ad
Giving is Good, Smart Giving is Great! - I’ve been fortunate for the life lessons I was taught by my parents. Both the big ones and the little ones. The one I have the earliest memory of is
Storytelling: From a Mere Nicety to a PR Necessity - Gone are the days when the “newness” of a news item was ample motivation to get people interested and mobilized to support a cause, buy a product
